Core Laboratories Nv Stock News

VANCOUVER, British Columbia, Dec. 17, 2021 (GLOBE NEWSWIRE) -- (CSE: CLC) Christina Lake Cannabis Corp. (the “Corporation” or “Christina Lake”) announces the extension to the expiry date of

Equities research analysts expect Core Laboratories (NYSE:CLB) to post $123.60 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Core Laboratories earnings, with the highest sales estimate coming in at $124.20 million and the lowest estimate coming in at $123.00 million. Core Laboratories posted sales of $113.75 million []

Core Laboratories N.V. found using ticker (CLB) now have 9 analysts covering the stock with the consensus suggesting a rating of ''Hold''. The target price ranges between 35 and 17.5 with the average target price sitting at 27.5. Given that the stocks previous close was at 24.65 this would imply there is a potential upside of 11.6%. There is a 50 day moving average of 26.92 while the 200 day moving average is 31.61. The market capitalisation for the company is $1,094m. Company Website: https://www.corelab.com [stock_market_widget type="chart" symbol="CLB" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. The company operates in two segments, Reservoir Description and Production Enhancement. The Reservoir Description segment includes the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients'' reservoirs.

Shares of Core Laboratories (NYSE:CLB) have received a consensus rating of Sell from the nine brokerages that are covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a sell rating and three have assigned a hold rating to the company. The average 12-month target price among analysts that have []

Price T Rowe Associates Inc. MD decreased its stake in Core Laboratories (NYSE:CLB) by 20.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,600 shares of the oil and gas companys stock after selling 2,200 shares during the period. Price []

Comerica Bank decreased its position in shares of Core Laboratories (NYSE:CLB) by 3.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,040 shares of the oil and gas companys stock after selling 1,590 shares during the quarter. Comerica Bank owned 0.09% of []

Louisiana State Employees Retirement System lifted its holdings in shares of Core Laboratories (NYSE:CLB) by 6.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,300 shares of the oil and gas companys stock after purchasing an additional 1,400 []

This move is a reversal from the day prior, which saw price move up. The post Core Laboratories N V (CLB): Price Now Near $24.18; Daily Chart Shows Downtrend on 20 Day Basis appeared first on ETF Daily News .

Brokerages expect Core Laboratories (NYSE:CLB) to announce $123.60 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Core Laboratories earnings, with estimates ranging from $123.00 million to $124.20 million. Core Laboratories reported sales of $113.75 million during the same quarter last year, which indicates a positive []

Royal Bank of Canada grew its stake in shares of Core Laboratories (NYSE:CLB) by 44.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 54,997 shares of the oil and gas companys stock after acquiring an additional 16,989 shares during the []

Shares of Core Laboratories (NYSE:CLB) gapped up before the market opened on Tuesday . The stock had previously closed at $25.07, but opened at $26.20. Core Laboratories shares last traded at $26.16, with a volume of 731 shares traded. Several research firms have recently issued reports on CLB. Morgan Stanley lowered their target price on […]

Brokerages forecast that Core Laboratories (NYSE:CLB) will post earnings of $0.20 per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Core Laboratories earnings, with estimates ranging from $0.19 to $0.20. Core Laboratories reported earnings of $0.18 per share during the same quarter last year, which suggests a positive year []

Core Laboratories N.V. (NYSE:CLB) price on Friday, November 19, fall -3.64% below its previous days close as a downside momentum from buyers pushed the stocks value to $24.38. A look at the stocks price movement, the close in the last trading session was $25.30. The beta value (5-Year monthly) was 3.06 while the PE ratio If Youre Considering Buying Core Laboratories N.V. (NYSE: CLB) Stock, Read This First. Read More »

Core Laboratories (NYSE:CLB)s stock price gapped down before the market opened on Friday . The stock had previously closed at $25.30, but opened at $24.36. Core Laboratories shares last traded at $24.51, with a volume of 1,481 shares. CLB has been the topic of several recent research reports. Piper Sandler reduced their price target on []

In the September quarter, Core Labs (CLB) generates $11.9 million as operating cash and its capex totals $3.1 million, leading to an $8.8-million free cash flow (FCF) recognition.